Repare Therapeutics and NCI Collaborate to Advance Camonsertib Development
核心洞察
Repare Therapeutics and the National Cancer Institute (NCI) have entered a Cooperative Research and Development Agreement (CRADA) to further develop camonsertib.
The collaboration aims to explore camonsertib's potential as an anticancer agent, including combination studies with radiation therapy and biomarker identification.
Camonsertib has shown promising anti-tumor activity in clinical trials, particularly in ATM (搜索)-mutated non-small cell lung cancer (搜索) and ATM-altered tumors.
Repare Therapeutics Inc. and the U.S. National Cancer Institute (NCI) are joining forces to advance the development of camonsertib, a potential best-in-class ATR inhibitor. The Cooperative Research and Development Agreement (CRADA) will allow the Cancer Therapy Evaluation Program (CTEP) of the NCI to collaborate with Repare to investigate camonsertib's full clinical potential as an anticancer agent.
Camonsertib's Clinical Promise
Camonsertib, an oral small molecule, has demonstrated significant anti-tumor activity in both preclinical and clinical studies. Current clinical trials are evaluating its safety and efficacy as a monotherapy and in combination with lunresertib, chemotherapy, and palliative external beam radiotherapy in patients with metastatic solid tumors (搜索). Notably, camonsertib monotherapy has shown encouraging progression-free survival in patients with ATM (搜索)-mutated non-small cell lung cancer (搜索). Phase 1 results combining camonsertib with radiotherapy have also yielded benefits, including complete responses, in patients with ATM-altered tumors across various histologies.
CTEP's Role in Advancing Cancer Therapies
The Cancer Therapy Evaluation Program (CTEP) facilitates the development of novel cancer therapies through collaborations with researchers and industry partners. CTEP's mission is to improve the lives of cancer patients by finding better ways to treat, control, and cure cancer. Under the CRADA, CTEP is particularly interested in combination studies involving camonsertib and various aspects of radiation therapy, as well as translational studies to identify predictive biomarkers.
Strategic Implications of the Collaboration
"This partnership with the CTEP allows the research community to investigate the full clinical potential of camonsertib more easily and we believe it will provide additional clinical development catalysts for the program," said Lloyd M. Segal, President and Chief Executive Officer of Repare.
The collaboration is poised to accelerate the clinical development of camonsertib, potentially broadening its application across various cancer types and treatment modalities. By combining Repare's expertise in precision oncology with CTEP's extensive resources and clinical network, the partnership aims to unlock new therapeutic strategies and improve outcomes for cancer patients.